Home » Alseres Pharma Wins FDA Approval to Lift Dose Level in Cethrin Phase I/IIa Clinical Trial
Alseres Pharma Wins FDA Approval to Lift Dose Level in Cethrin Phase I/IIa Clinical Trial
Alseres Pharmaceuticals, Inc. on Wednesday said that the U.S. Food and Drug Administration authorized an increase in the dose level of Cethrin to 9 mg in the company’s ongoing Phase I/IIa clinical study for the treatment of acute spinal cord injury.
RTTNews
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May